Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Satisfactory completion of KKP's sponsored KRN23-INT-001 clinical trial~2. eGFR ≥ 60 mL/min~3. Corrected Ca \< 10.8 mg/dL~4. For female of child-bearing potential, a negative serum pregnancy test~5. A willingness to utilize adequate contraception and not become pregnant \[or to have their partner(s) become pregnant\] during the study~6. Additional inclusion criteria apply~Exclusion Criteria:~1. Subject experienced a safety-related event in the KRN23-INT-001 study~2. Pregnant or lactating female subject or pregnant or female planning to become pregnant during the study~3. Receipt of a live (attenuated) vaccine (except for influenza vaccines) during the course of the KRN23-INT-001 study and/or of this study~4. Condition which could present a concern for either the subject's safety or difficulty with data interpretation~5. Additional exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KRN23 (Type: EXPERIMENTAL): Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).